Trial Profile
A prospective, open-label, parallel group, placebo-controlled study evaluating the pharmacodynamic effect of rosuvastatin-induced hypolipidemic and vasoprotective response in patients with mixed hyperlipidemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Biomarker; Pharmacodynamics
- 27 Nov 2015 New trial record